Objective To study the effect of villiciguat on cardiac function,soluble human stromal cleavage 2 (sST2) and brain natriuretic peptide (BNP) in patients with heart failure with reduced ejection fraction (HFrEF).Methods A total of 108 patients with HFrEF in Chongqing Red Cross Hospital from July to December 2022 were selected as the research objects.According to whether the patients were treated with villiciguat,they were divided into the observation group (n=48) and control group (n=60).The patients in the control group were treated with HFrEF routine therapy,and the patients in the observation group were treated with villiciguat on the basis of the routine therapy.The treatment time was three months.The echo-cardiography,levels of serum sST2 and BNP were detected before and after treatment,and the incidence of ad-verse reactions during treatment was compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant (93.75％ vs.76.67％,P<0.05).Before treatment,there were no significant differences in cardiac function in-dexes and serum sST2 and BNP levels between the two groups (P>0.05).After treatment,the left atrial di-ameter (LAD),left ventricular end-systolic diameter (LVESD),left ventricular end-diastolic diameter (LVEDD),serum sST2 and BNP levels in the two groups were lower than those before treatment,the left ventricular ejection fraction (LVEF) was higher than that before treatment,and the above indexes in the ob-servation group were better than those in the control group,the differences were statistically significant (P<0.05).Conclusion On the basis of routine therapy,villiciguat can effectively improve the curative effect ofHFrEF patients and improve the cardiac function of patients.
关键词
可溶性人基质裂解素2/维立西呱/心功能/射血分数降低性心力衰竭/脑钠肽
Key words
soluble human stromal cleavage 2/villiciguat/cardiac function/heart failure with reduced ejection fraction/brain natriuretic peptide
维普
万方数据